Expert View: Wearable Technology And The FDA Adoption Curve
This article was originally published in Scrip
Executive Summary
The US FDA recently announced that it will carefully consider the value of mobile technology in clinical research. By and large, the process of testing and approving new drugs and therapies has remained unchanged for the past 50 years. Today, data collected in everyday devices like smartphones and wearable fitness trackers could make clinical trials safer for patients and provide meaningful data to the FDA, write Barbara Elashoff and Glen de Vries of Medidata Solutions.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.